Introduction
A number of botulinum toxin type A (BoNT-A) formulations have been approved for the treatment of glabellar lines (wrinkles that appear between the eyebrows, also known as frown lines) worldwide, with additional indications, such as lateral canthal lines (also known as crow’s feet), approved in some countries [AbobotulinumtoxinA (aboBoNT-A; DysportTo address this gap, the aim of the current study was to demonstrate the short- and long-term efficacy and safety of repeated administrations of aboBoNT-A 50 U in the treatment of moderate-to-severe glabellar lines in Chinese patients. The superiority of aboBoNT-A compared with placebo, and non-inferiority of aboBoNT-A compared with an active comparator (onabotulinumtoxinA [onaBoNT-A]; Botox